Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma
- 24 October 2017
- journal article
- research article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 32 (1) , 69-74
Abstract
To explore the clinical utility of PSMA-targeted 18F-DCFPyL PET/CT in patients with metastatic urothelial carcinoma.Keywords
Funding Information
- National Institutes of Health (CA134675, CA183031)
This publication has 32 references indexed in Scilit:
- Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate CancerMolecular Imaging and Biology, 2015
- Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumorsEJNMMI Research, 2015
- First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate CancerMolecular Imaging and Biology, 2015
- Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysisTumor Biology, 2015
- Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy aloneBJU International, 2014
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genomeBMC Bioinformatics, 2011
- MapSplice: Accurate mapping of RNA-seq reads for splice junction discoveryNucleic Acids Research, 2010
- Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Neovasculature of Renal NeoplasmsUrology, 2007
- Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid TumorsJournal of Clinical Oncology, 2007